Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 310.4
(-0.06%)
SEK 310.4
(-0.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.4 Billion SEK | -8.68% |
| 2022 | 2.63 Billion SEK | -1.53% |
| 2021 | 2.67 Billion SEK | -17.44% |
| 2020 | 3.24 Billion SEK | -1.79% |
| 2019 | 3.3 Billion SEK | 36.65% |
| 2018 | 2.41 Billion SEK | 110.5% |
| 2017 | 1.14 Billion SEK | 41.97% |
| 2016 | 809.07 Million SEK | 1082.97% |
| 2015 | 68.39 Million SEK | 125.54% |
| 2014 | -267.83 Million SEK | -188.13% |
| 2013 | -92.95 Million SEK | 7.86% |
| 2012 | -100.88 Million SEK | -662.74% |
| 2011 | 17.92 Million SEK | 117.17% |
| 2010 | -104.4 Million SEK | -421.85% |
| 2009 | 32.43 Million SEK | 109.67% |
| 2008 | -335.36 Million SEK | -524.59% |
| 2007 | 78.98 Million SEK | -14.77% |
| 2006 | 92.66 Million SEK | -47.41% |
| 2005 | 176.22 Million SEK | 765.21% |
| 2004 | -26.49 Million SEK | -107.16% |
| 2003 | 369.72 Million SEK | 1131.47% |
| 2002 | -35.84 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 800 Million SEK | -22.03% |
| 2024 Q2 | 224 Million SEK | -72.0% |
| 2024 Q3 | 1.46 Billion SEK | 553.57% |
| 2023 Q2 | 222 Million SEK | -79.19% |
| 2023 Q4 | 1.02 Billion SEK | 991.49% |
| 2023 Q3 | 94 Million SEK | -57.66% |
| 2023 Q1 | 1.06 Billion SEK | -23.02% |
| 2023 FY | 2.4 Billion SEK | -8.68% |
| 2022 Q3 | 451 Million SEK | 74.81% |
| 2022 Q4 | 1.38 Billion SEK | 207.32% |
| 2022 Q2 | 258 Million SEK | -52.49% |
| 2022 FY | 2.63 Billion SEK | -1.53% |
| 2022 Q1 | 543 Million SEK | -56.24% |
| 2021 Q1 | 696 Million SEK | -53.66% |
| 2021 Q4 | 1.24 Billion SEK | 162.37% |
| 2021 Q3 | 473 Million SEK | 76.49% |
| 2021 Q2 | 268 Million SEK | -61.49% |
| 2021 FY | 2.67 Billion SEK | -17.44% |
| 2020 Q3 | 278 Million SEK | -1.77% |
| 2020 Q1 | 1.18 Billion SEK | -13.09% |
| 2020 Q2 | 283 Million SEK | -76.06% |
| 2020 FY | 3.24 Billion SEK | -1.79% |
| 2020 Q4 | 1.5 Billion SEK | 440.29% |
| 2019 Q3 | 542 Million SEK | 8.62% |
| 2019 Q4 | 1.36 Billion SEK | 150.92% |
| 2019 FY | 3.3 Billion SEK | 36.65% |
| 2019 Q1 | 903 Million SEK | 51.82% |
| 2019 Q2 | 499 Million SEK | -44.74% |
| 2018 FY | 2.41 Billion SEK | 110.5% |
| 2018 Q3 | 623 Million SEK | -9.05% |
| 2018 Q2 | 685 Million SEK | 33.01% |
| 2018 Q4 | 594.79 Million SEK | -4.53% |
| 2018 Q1 | 515 Million SEK | 44.01% |
| 2017 FY | 1.14 Billion SEK | 41.97% |
| 2017 Q4 | 357.61 Million SEK | 10.37% |
| 2017 Q3 | 324 Million SEK | 31.71% |
| 2017 Q2 | 246 Million SEK | 25.51% |
| 2017 Q1 | 196 Million SEK | 97.84% |
| 2016 FY | 809.07 Million SEK | 1082.97% |
| 2016 Q3 | 143 Million SEK | -46.04% |
| 2016 Q1 | 301 Million SEK | 3597.15% |
| 2016 Q2 | 265 Million SEK | -11.96% |
| 2016 Q4 | 99.07 Million SEK | -30.72% |
| 2015 Q3 | 5 Million SEK | -44.44% |
| 2015 FY | 68.39 Million SEK | 125.54% |
| 2015 Q1 | 106 Million SEK | 708.08% |
| 2015 Q4 | -8.6 Million SEK | -272.14% |
| 2015 Q2 | 9 Million SEK | -91.51% |
| 2014 Q4 | -17.43 Million SEK | -133.08% |
| 2014 FY | -267.83 Million SEK | -188.13% |
| 2014 Q3 | 52.7 Million SEK | 105.86% |
| 2014 Q2 | 25.6 Million SEK | 107.79% |
| 2014 Q1 | -328.7 Million SEK | -2342.78% |
| 2013 Q2 | -10.9 Million SEK | 10.66% |
| 2013 Q1 | -12.2 Million SEK | 91.45% |
| 2013 Q4 | -13.45 Million SEK | 76.14% |
| 2013 FY | -92.95 Million SEK | 7.86% |
| 2013 Q3 | -56.4 Million SEK | -417.43% |
| 2012 Q3 | -45.4 Million SEK | 32.94% |
| 2012 Q4 | -142.68 Million SEK | -214.28% |
| 2012 FY | -100.88 Million SEK | -662.74% |
| 2012 Q1 | 154.8 Million SEK | 1208.87% |
| 2012 Q2 | -67.7 Million SEK | -143.73% |
| 2011 Q2 | 113.4 Million SEK | 264.59% |
| 2011 Q3 | -38.4 Million SEK | -133.86% |
| 2011 FY | 17.92 Million SEK | 117.17% |
| 2011 Q4 | 11.82 Million SEK | 130.8% |
| 2011 Q1 | -68.9 Million SEK | -434.11% |
| 2010 FY | -104.4 Million SEK | -421.85% |
| 2010 Q1 | -52.4 Million SEK | -266.68% |
| 2010 Q2 | -11.6 Million SEK | 77.86% |
| 2010 Q4 | -12.9 Million SEK | 53.09% |
| 2010 Q3 | -27.5 Million SEK | -137.07% |
| 2009 Q3 | 7.9 Million SEK | -52.98% |
| 2009 Q1 | -23.7 Million SEK | 0.0% |
| 2009 Q4 | 31.43 Million SEK | 297.94% |
| 2009 FY | 32.43 Million SEK | 109.67% |
| 2009 Q2 | 16.8 Million SEK | 170.89% |
| 2008 FY | -335.36 Million SEK | -524.59% |
| 2007 FY | 78.98 Million SEK | -14.77% |
| 2006 FY | 92.66 Million SEK | -47.41% |
| 2005 FY | 176.22 Million SEK | 765.21% |
| 2004 FY | -26.49 Million SEK | -107.16% |
| 2003 FY | 369.72 Million SEK | 1131.47% |
| 2002 FY | -35.84 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 17695.501% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 6581.556% |
| BioGaia AB (publ) | 365.35 Million SEK | -559.364% |
| Enzymatica AB (publ) | -49.72 Million SEK | 4944.353% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 5499.771% |
| Gabather AB (publ) | -9.43 Million SEK | 25627.18% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 6832.059% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 11520.851% |
| Nanexa AB (publ) | -76.39 Million SEK | 3253.224% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 15737.78% |
| ODI Pharma AB | 355.97 Thousand SEK | -676640.521% |
| Orexo AB (publ) | -128.3 Million SEK | 1977.631% |
| Probi AB (publ) | 16.81 Million SEK | -14223.087% |
| Swedencare AB (publ) | 58.6 Million SEK | -4010.922% |
| Toleranzia AB | -7.45 Million SEK | 32396.554% |
| Vivesto AB | -367.03 Million SEK | 756.35% |